Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (22399)	6/17/1998 6:17:00 PM
From: jayhawk969	Respond to of 32384

RB, "The letter identified certain deficiencies in the application related to safety, efficacy, manufacturing and product characterization. The key word to me is application, deficiencies in the application--not the product.

To: Russian Bear who wrote (22399)	6/17/1998 6:18:00 PM
From: celeryroot.com	Respond to of 32384

I do not know what the situation is in this case but this is not unusual. It could be a labeling problem or numerous nits. If you look back over other advisery approvals you will see they usually have a few questions attached which need to be ironed out. What I do think is that this is very poorly written and leaves a big question mark.